Skip to main content
. 2023 Apr 29;16:42. doi: 10.1186/s13045-023-01437-1

Fig. 1.

Fig. 1

Trial profile. HSCT hematopoietic stem cell transplantation, GVHD graft-versus-host disease, AML acute myeloid leukemia, VAH Venetoclax Combined With Azacitidine And Homoharringtonine, CRc composite complete remission, NR non-remission, PR partial remission, HD Ara-c high-dose cytarabine, OS overall survival